GLUE · Monte Rosa Therapeutics

The thesis

Monte Rosa Therapeutics' third-quarter report on 5 November 2026 shows Novartis milestones funding the business, but the case for its inflammation drug MRT-8102 still rests on GFORCE-2, a heart-disease trial that the company guides to start in the first half of 2027. Until that trial starts and reads out, the shares trade on milestone income, spending and start dates rather than on cardiovascular evidence.

The company reported collaboration revenue of $54.4 million against $12.8 million a year earlier, mainly from the $50.0 million Novartis milestone for the Sjögren's disease study, and net income of $3.1 million against a $27.1 million net loss in the third quarter of 2025 (company release, 5 November 2026). Research and development expense was $45.4 million, below the $48.0 million of the second quarter. Cash, equivalents, restricted cash and marketable securities were $582.6 million at 30 September 2026, down from $626.0 million at 30 June 2026, with runway guided into 2029. The company says that balance excludes the $50 million and $37.5 million MRT-6160 milestones.

The adjusted daily close was $10.50 on 10 November 2026, 58.5% below the 52-week high of $25.31, with a three-month price change of −33.7% and a 14-day relative strength index of 37.9. The story is well known: the MRT-8102 Phase 1 data have been public since 1 October 2026, the milestone news has been absorbed, and the next dated clinical event is a gout trial start guided for the fourth quarter of 2026. Novo Nordisk's ZEUS trial of ziltivekimab, which targets the same inflammatory pathway, reported a major adverse cardiovascular event hazard ratio of 0.99 (TCTMD, 3 August 2026), so outcomes evidence in heart disease, not inflammation markers, settles the case.

Bullish and bearish views on Monte Rosa Therapeutics, Inc.

The bull case on Monte Rosa Therapeutics, Inc. (GLUE), in brief: milestones turned the quarter profitable. The bear case: the heart-disease trial is still months away.

Bull case

• Milestones turned the quarter profitable. Collaboration revenue was $54.4 million in the third quarter, and the $37.5 million psoriatic arthritis milestone announced on 28 October 2026 falls outside that quarter and outside the reported cash balance (company release, 5 November 2026).
• Novartis funds MRT-6160 Phase 2. Novartis conducts and funds Phase 2 development, and Monte Rosa co-funds Phase 3 and shares 30% of U.S. profits and losses. The agreement allows up to $2.1 billion in development, regulatory and sales milestones (company filings).
• Spending eased and runway held. Research and development expense fell to $45.4 million from $48.0 million in the second quarter, and cash of $582.6 million is guided to last into 2029 (company release, 5 November 2026).
• MRT-8102 safety was clean in Phase 1. GFORCE-1 enrolled 108 obese subjects with elevated cardiovascular risk. Median high-sensitivity C-reactive protein fell 85%, and adverse events were 33% on MRT-8102 against 30% on placebo, with no serious events (company release, 1 October 2026).
• Sell-side targets remain far above the share price. HC Wainwright reiterated Buy with a $25 target on 5 October 2026. Wells Fargo maintained its rating and lowered its target to $25 on 6 November 2026 (Benzinga headline).

Bear case

• The heart-disease trial is still months away. The company guides GFORCE-2, a Phase 2b trial in stable coronary artery disease, to start in the first half of 2027 (company release, 5 November 2026). Earlier guidance, in the first-quarter 2026 release, was the second half of 2026.
• Another timeline moved. The third-quarter release says the investigational new drug filing for the next-generation NEK7 molecular glue degrader is now anticipated in 2027, attributed to prioritizing the MRT-8102 Phase 2 starts (company release, 5 November 2026).
• Inflammation markers have not predicted outcomes in this class. ZEUS reported a hazard ratio of 0.99 (TCTMD, 3 August 2026). A four-week Phase 1 study in 108 subjects cannot show event reduction.
• Cash is declining and milestones are irregular. Cash fell $43.4 million to $582.6 million between 30 June 2026 and 30 September 2026. Nine-month research and development expense was $137.4 million against $99.5 million a year earlier (Quartr and Panabee summaries of the release).
• An analyst cut a target. Wells Fargo lowered its price target to $25 on 6 November 2026 (Benzinga headline), and the shares have fallen 33.7% over three months to the 10 November 2026 close.

Price setup

The adjusted daily close on 10 November 2026 was $10.50 (split- and dividend-adjusted daily bars). The 52-week high is $25.31, so the shares sit 58.5% below it. The close of $10.12 on 15 October 2026 is the recent low, and the close on 28 October 2026 was $10.85, so the shares have traded in a narrow range around $10 to $11 for about four weeks.

The 14-day relative strength index was 37.9 on 10 November 2026, down from 56.0 on 28 October 2026, which shows the shares weakening after the quarterly report. Analyst targets of $25 from both HC Wainwright and Wells Fargo are more than double the last close.

Crowding evidence is limited. No heavy retail attention, insider selling or share issuance into strength shows in the news flow; the company disclosed inducement equity awards to new employees on 3 November 2026 and 5 November 2026, which are routine hiring grants.

Catalysts ahead

• ~31 December 2026 (est.): Updated MRT-2359 Phase 1/2 data for the enzalutamide expansion arm in metastatic castration-resistant prostate cancer (company guidance: by year-end 2026). The only dated data event inside the window; it shows whether the oncology programme adds value beyond MRT-8102 and MRT-6160.
• Q4 2026: GEMINI-1 Phase 2 start of MRT-8102 in gout, with initial data guided for H2 2027. The nearest clinical step for MRT-8102 outside heart disease; a slip past Q1 2027 would weaken the timeline.
• H1 2027: GFORCE-2 Phase 2b start in stable coronary artery disease; GALAXY-1 start in hidradenitis suppurativa. GFORCE-2 is the first trial built to test the cardiovascular case for MRT-8102.

What would change the view

A daily close above $12.48, 21% above the last close (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.

What it trades with

Monte Rosa trades on its own clinical and partner news. The read-across that matters is Novo Nordisk's ziltivekimab programme: the HERMES and ARTEMIS outcomes readouts, guided for the first half of 2027, re-test inflammation-marker assets on hard endpoints. Moves in small-cap biotech indices and in other protein-degradation names (for example, Novartis-partnered programmes) share the same funding and risk appetite, but no measured correlation is cited here.